Rapid Micro Biosystems, Inc (RPID) News & EventsRPIDRapid Micro Biosystems, Inc

Raises FY26 System Validation View to At Least 27 Validations

Raises FY26 system validation view to at least 27 validations from 25 validations. Spignesi continued, "As we look to the second half of 2026, we remain encouraged by strong customer engagement, continued momentum in multi-system and enterprise deployment opportunities, and an expanding contribution from our collaboration with MilliporeSigma. Combined with favorable industry tailwinds, including increased adoption of automation and ongoing U.S. reshoring and biomanufacturing capacity expansion, we believe we are well positioned to achieve our full-year objectives and enter 2027 with positive momentum."

Company Reports Q2 Revenue of $8.05M, Beating Expectations

Reports Q2 revenue $8.05M, consensus $7.88M. "Our second quarter results reflect continued execution against the strategic and financial priorities we outlined at the beginning of the year," said Robert Spignesi, President and CEO. "Total revenue increased 11%, recurring revenue grew 14% and consumables achieved quarterly records in both units and revenue. Importantly, we delivered record second-quarter total gross margin of 15%, marking a positive inflection that reflects meaningful progress against our margin expansion initiatives and supports our path to positive cash flow."

Lake Street Lowers Rapid Micro Price Target to $7

Lake Street lowered the firm's price target on Rapid Micro Biosystems to $7 from $8 and keeps a Buy rating on the shares after the company announced an underwritten public offering and concurrent registered direct offering with upfront gross proceeds of about $9.8M and potential additional gross proceeds of about $21.7M if the accompanying warrants are exercised in cash. The firm lowered its price target to reflect the increase in share count resulting from the financing.